Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Flexion Therapeutics Inc (NASDAQ:FLXN)

19.59
Delayed Data
As of 3:59pm ET
 +0.40 / +2.08%
Today’s Change
10.24
Today|||52-Week Range
29.41
+3.00%
Year-to-Date
2 Oversold Biopharmas With Big 2017 Upsides
May 22 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close19.19
Today’s open19.19
Day’s range18.54 - 19.67
Volume982,188
Average volume (3 months)569,332
Market cap$559.6M
Dividend yield--
Data as of 3:59pm ET, 05/23/2017

Growth & Valuation

Earnings growth (last year)-32.09%
Earnings growth (this year)-29.46%
Earnings growth (next 5 years)--
Revenue growth (last year)--
P/E ratioNM
Price/Sales--
Price/Book2.98

Competitors

 Today’s
change
Today’s
% change
PTCTPTC Therapeutics Inc+0.09+0.67%
INOInovio Pharmaceutica...+0.04+0.56%
AKBAAkebia Therapeutics ...+0.02+0.14%
CARACara Therapeutics In...-0.44-2.50%
Data as of 3:59pm ET, 05/23/2017

Financials

Next reporting dateAugust 10, 2017
EPS forecast (this quarter)-$0.83
Annual revenue (last year)$0.00
Annual profit (last year)-$71.9M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer, CFO &
Director
Michael D. Clayman
Senior Vice President-
CMC Operations
Dan Leblanc
Corporate headquarters
Burlington, Massachusetts

Forecasts